专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20020068731A1 Prevention and treatment of cardiovascular pathologies with tamoxifen analogues 审中-公开
标题翻译：用他莫昔芬类似物预防和治疗心血管病变
公开(公告)号：US20020068731A1
公开(公告)日：2002-06-06
申请号：US09754775
申请日：2001-01-04
申请人： NeoRx Corporation
发明人： David J. Grainger , James C. Metcalfe , Lawrence L. Kunz , Robert W. Schroff
IPC分类号： A61K031/55 , A61K031/445 , A61K031/40 , A61K031/137
CPC分类号： A61K31/445 , A61K31/135 , A61K31/138 , A61K31/38 , A61K31/40 , G01N2800/32 , G01N2800/324 , Y10S514/866
摘要： A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): 1 wherein Z is CnullO or a covalent bond; Y is H or O(C1-C4)alkyl, R1 and R2 are individually (C1-C4)allyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H, R5 is I, O(C1-C4)alkyl or H and R6 is I, O(C1-C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to elevate the level of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene, toremifene or salts thereof. Further provided is a method for identifying an agent that elevates the level of TGF-beta. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (I).
摘要翻译：一种治疗或预防心血管病变的方法，其通过给予式（I）化合物：其中Z为C = O或共价键; Y为H或O（C1-C4）烷基，R1和R2分别为（C1-C4）烯丙基或与N一起为饱和杂环基，R3为乙基或氯乙基，R4为H，R5为I，O -C4）烷基或H，R6是I，O（C1-C4）烷基或H，条件是当R4，R5和R6是H时，R3不是乙基; 提供有效地提高TGF-β水平以治疗和/或预防诸如动脉粥样硬化，血栓形成，心肌梗塞和中风的病症的药学上可接受的盐或其药学上可接受的盐。有用的化合物包括异昔芬，托瑞米芬或其盐。还提供了用于鉴定提高TGF-β水平的试剂的方法。本发明的另一个实施方案是用于在体外测定TGF-β的测定或试剂盒。还提供了一种治疗方法，其包括使用给予他莫昔芬或其结构类似物（包括式（I）的化合物）来抑制与程序性血管创伤相关的平滑肌细胞增殖。

2. 发明申请

US20020086896A1 Therapeutic inhibitor of vascular smooth muscle cells 失效
公开(公告)号：US20020086896A1
公开(公告)日：2002-07-04
申请号：US10024885
申请日：2001-12-18
申请人： NeoRx Corporation
发明人： Lawrence L. Kunz , Richard A. Klein , John M. Reno
IPC分类号： A61K031/407 , A61K031/337
CPC分类号： A61K9/0024 , A61K31/00 , A61K31/04 , A61K31/131 , A61K31/135 , A61K31/138 , A61K31/165 , A61K31/17 , A61K31/337 , A61K31/352 , A61K31/365 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/407 , A61K31/519 , A61K31/551 , A61K31/704 , A61K47/50 , A61K47/51 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6831 , A61K47/6843 , A61K47/6923 , A61K47/6927 , A61K47/6929 , A61K47/6957 , A61L31/148 , A61L31/16 , A61L2300/416 , A61L2300/602 , A61L2300/622 , A61L2300/63 , G01N2800/323 , Y10S977/904
摘要： Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

3. 发明申请

US20020040064A1 Therapeutic inhibitor of vascular smooth muscle cells 失效
标题翻译：血管平滑肌细胞治疗抑制剂
公开(公告)号：US20020040064A1
公开(公告)日：2002-04-04
申请号：US09910387
申请日：2001-07-20
申请人： NeoRx Corporation.
发明人： Lawrence L. Kunz , Richard A. Klein
IPC分类号： A61K031/135
CPC分类号： A61K31/04 , A61K9/0024 , A61K31/00 , A61K31/131 , A61K31/135 , A61K31/138 , A61K31/165 , A61K31/17 , A61K31/337 , A61K31/352 , A61K31/365 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/407 , A61K31/519 , A61K31/551 , A61K31/704 , A61K47/50 , A61K47/51 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6831 , A61K47/6843 , A61K47/6923 , A61K47/6927 , A61K47/6957 , A61L31/148 , A61L31/16 , A61L2300/416 , A61L2300/602 , A61L2300/604 , A61L2300/606 , B82Y5/00 , G01N2800/323 , Y10S977/775 , Y10S977/808 , Y10S977/905 , Y10S977/906 , Y10S977/916
摘要： Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
摘要翻译：提供了用于在哺乳动物宿主中的血管创伤或疾病之后抑制狭窄的方法，包括向宿主施用治疗有效剂量的含有血管平滑肌结合蛋白的治疗性缀合物，其以特定方式与血管平滑的细胞表面相关联肌肉细胞，与抑制肌肉细胞的细胞活性的治疗剂剂型偶联。还提供了用于通过抑制平滑肌细胞收缩导致血管腔的扩张和固定的血管平滑肌细胞的治疗剂的直接和/或靶向递送的方法，从而构成生物支架。

4. 发明申请

US20030203958A1 Therapeutic inhibitor of vascular smooth muscle cells 失效
公开(公告)号：US20030203958A1
公开(公告)日：2003-10-30
申请号：US10330834
申请日：2002-12-27
申请人： NeoRx Corporation
发明人： Lawrence L. Kunz , Richard A. Klein , John M. Reno
IPC分类号： A61K031/407 , A61K031/337
CPC分类号： A61K9/0024 , A61K31/00 , A61K31/04 , A61K31/131 , A61K31/135 , A61K31/138 , A61K31/165 , A61K31/17 , A61K31/337 , A61K31/352 , A61K31/365 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/407 , A61K31/519 , A61K31/551 , A61K31/704 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6831 , A61K47/6843 , A61K47/6849 , A61K47/6923 , A61K47/6927 , A61L31/08 , A61L31/148 , A61L31/16 , A61L2300/416 , A61L2300/432 , A61L2300/602 , A61L2300/606 , A61L2300/622 , G01N2800/323 , Y10S977/906 , Y10S977/915 , Y10S977/92
摘要： Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

5. 发明申请

US20020013275A1 Therapeutic inhibitor of vascular smooth muscle cells 失效
标题翻译：血管平滑肌细胞治疗抑制剂
公开(公告)号：US20020013275A1
公开(公告)日：2002-01-31
申请号：US09910388
申请日：2001-07-20
申请人： NeoRx Corporation
发明人： Lawrence L. Kunz , Richard A. Klein , John M. Reno , David J. Grainger , James C. Metcalfe , Peter L. Weissberg , Peter G. Anderson
IPC分类号： A61K038/00 , A01N037/18 , A61K031/40 , A01N043/38
CPC分类号： A61K9/0024 , A61K31/00 , A61K31/135 , A61K31/138 , A61K31/337 , A61K31/40 , A61K31/4025 , A61K31/4035 , A61K31/407 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6831 , A61K47/6843 , A61K47/6927 , A61K47/6931 , G01N2800/323
摘要： Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.
摘要翻译：提供了用于在哺乳动物宿主中的血管创伤或疾病之后抑制狭窄的方法，包括向宿主施用治疗有效剂量的含有血管平滑肌结合蛋白的治疗性缀合物，其以特定方式与血管平滑的细胞表面相关联肌肉细胞，与抑制肌肉细胞的细胞活性的治疗剂剂型偶联。还提供了用于通过抑制平滑肌细胞收缩导致血管腔的扩张和固定的血管平滑肌细胞的治疗剂的直接和/或靶向递送的方法，从而构成生物支架。还讨论了体内血管平滑肌细胞增殖调节的机制，影响这些药物使用的机制和方案的试剂。

6. 发明申请

US20030083733A1 Therapeutic inhibitor of vascular smooth muscle cells 审中-公开
公开(公告)号：US20030083733A1
公开(公告)日：2003-05-01
申请号：US10190211
申请日：2002-07-03
申请人： NeoRx Corporation
发明人： Lawrence L. Kunz
IPC分类号： A61F002/06 , A61M031/00
CPC分类号： B82Y5/00 , A61K47/6849 , A61K47/6929
摘要： Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式